Prostacyclin (PGI 2 ) plays important roles in hemostasis both as a vasodilator and an endogenous inhibitor of platelet aggregation. PGI 2 functions in these roles through a specific IP receptor, a G protein-coupled receptor linked to G s and increases in cAMP. Here, we report that intracellular prostacyclin formed by expressing prostacyclin synthase in human embryonic kidney 293 cells promotes apoptosis by activating endogenous peroxisome proliferator-activated receptor ␦ (PPAR␦). In contrast, treatment of cells with extracellular prostacyclin or dibutyryl cAMP actually reduced apoptosis. On the contrary, treatment of the cells with RpcAMP (adenosine 3,5-cyclic monophosphothioate, Rp-isomer), an antagonist of cAMP, enhanced prostacyclin-mediated apoptosis. The expression of an L431A/ G434A mutant of PPAR␦ completely blocked prostacyclin-mediated PPAR␦ activation and apoptosis. These observations indicate that prostacyclin can act through endogenous PPAR␦ as a second signaling pathway that controls cell fate.
9.9 l of LipofectAMINE (Life Technologies, Inc.) with serum-free DMEM, and cells were cultured for 5 h. Subsequently, DMEM containing 20% FBS ("medium B") was added, and cells were cultured with or without 100 M aspirin or 100 M U46619. After 36 h, the cells were rinsed with PBS, fixed in 3.7% formaldehyde for 10 min, and washed with PBS three times. The cells were then incubated with anti-PGIS antibody P4 for 2 h, and with anti-rabbit IgG-Texas Red for 1 h at 37°C, washed three times with PBS containing 2% FBS, stained with 0.3 mM Hoechst 33258 and observed under fluorescent microscopy.
Immunoblotting-Total cellular extracts from the transfected cells were prepared by lysing cells in 1% SDS, 5 mM EDTA, 5 mM EGTA, 1 mM dithiothreitol, 200 mM phenylmethanesulfonyl fluoride, and 100 mM leupeptin. Protein from 1.0 ϫ 10 4 cells was separated by 10% SDSpolyacrylamide gel electrophoresis and electrotransferred onto Immobilon-P polyvinylidene difluoride transfer membranes (Millipore, Bedford, MA). Filters were blocked overnight with Tris-buffered saline (TBS) containing 5% skim milk (Bio-Rad, Hercules, CA) and 3% bovine serum albumin (Seikagaku Kogyo Co., Tokyo, Japan) at 4°C. Immunostaining steps were performed in TBS containing 0.05% Tween 20 and 3% bovine serum albumin at room temperature. Filters were incubated with primary and secondary antibodies for 1 h each. Filters were washed in TBS containing 0.05% Tween 20 four times for 10 min between each step and were developed with ECL reagent (Amersham Pharmacia Biotech).
Cell Culture and Transfection-HEK-293 (29) , CV-1, and bovine aortic endothelial cells (BAEC) (30) (1.2 ϫ 10 4 cells/cm 2 ) were cultured in medium A. Caco-2 cells (1.0 ϫ 10 5 cells/30-mm dish coated with collagen) were cultured in RPMI 1640 supplemented with 10% FBS, 100 units/ml penicillin, and 100 mg/ml streptomycin. For expression of PGISwt, PGISC441A, COX-1, and COX-2, plasmid vectors pCMV/ PGISWT (29) , pCMV/PGISC441A (29) , pcDNACOX-1 (31) , and pcDNACOX-2 (31) were used, respectively. HEK-293, Caco-2 and CV-1 cells were transfected with DNA using LipofectAMINE. BAEC were transfected using TransIT LT-1 (PanVera Co., Madison, WI). Transfections were performed in a ratio of 1 g of DNA to 3.0 l of reagent, and cells were incubated in serum-free medium at 37°C for 5 h. Subsequently, medium B or RPMI 1640 containing 20% FBS was added, and cells were grown for 12-72 h before analysis of apoptosis.
Measurement of Cell Viability-Cell viability was determined by trypan blue exclusion. 10 l of a 0.5% solution of the dye was added to 100 l of cell suspension (1.0 ϫ 10 4 cells/100 l). The suspension was then applied to a hemacytometer, and both viable and nonviable cells were counted. A minimum of 300 cells was counted for each data point.
Assay of DNA Fragments-A cell death detection enzyme-linked immunosorbent assay (ELISA) (Roche Molecular Biochemicals, Indianapolis, IN) was performed to determine the apoptotic index by detecting nucleosome breakdown, the histone-associated DNA fragments (monoand oligonucleosomes) generated by apoptotic cells. HEK-293 cells (8.0 ϫ 10 4 cells/well in 12-well plates) were plated in medium A and grown for 12 h. Cells were washed with PBS, transfected with PGISwt expression vector or mock vector, and cultured for 72 h. The cells were collected along with the floating cells and used to prepare the cytosol fractions. A volume of 10 l of these cytosolic fractions were incubated in anti-histone antibody-coated wells (96-well plates), and the histones of the DNA fragments were detected by using 2,2Ј-azino-di-(3-ethylbenzathiazoline sulfonate). The reaction products in each of the 96 wells were read using a Bio-Rad microplate reader (model 3550-UV). To assess DNA ladder formation, low molecular weight DNA was extracted from 1.8 ϫ 10 6 cells (both floating and adherent) using ApoLadder EX kit (Takara Shuzo Co., Tokyo). The extracted DNA fragments were applied to a 1.5% agarose gel, separated electrophoretically, and visualized with ethidium bromide.
Measurement of Apoptosis-Apoptotic cells were distinguished by their characteristic morphological changes such as membrane blebbing and cell body shrinkage. HEK-293, CV-1, or Caco-2 cells (2.0 ϫ 10 5 cells/well in 6-well plates) were plated with the respective serum-supplemented media and grown for 12 h. Cells were washed with PBS, cotransfected with 1 g of ␤-galactosidase expression vector, and 2.5 g of PGISwt or PGISC441A expression vector and cultured for 5 h in serum-free medium. Subsequently, medium B was added and cells were grown for 60 h. The cells were stained with X-gal (5-bromo-4-chloro-3-indolyl ␤-galactoside) solution (PBS containing 5 mM X-gal, 1 mM MgCl 2 , 10 mM KCl, 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 -3H 2 O) at 37°C for 3 h and scored for apoptotic cells. For measurement of effects of reagents on apoptosis, cells (2.0 ϫ 10 5 cells/well in 6-well plates) cotransfected with 1 g of ␤-galactosidase and 2.5 g of PGISwt or PGISC441A were cultured in serum-free medium containing several concentrations of iloprost, dbcAMP, H-7, or RpcAMP for 24 h at 37°C, washed gently with PBS, and stained with X-gal. For analysis of effects of PPAR␦ on apoptosis, HEK-293 cells (8.0 ϫ 10 4 cells/well in 12-well plates) were cotransfected with 0.1 g of ␤-galactosidase expression vector and 0.7 g of expression vector for PPAR␦ or mutant PPAR␦ and PGISwt, PGISC441A, or mock vector using LipofectAMINE. The total amount of DNA was kept at 2 g by the addition of control DNA (pCMV-7). After 24 h of transfection, cells were stained with X-gal and apoptosis was measured. The cells underwent apoptosis were indicated by a percentage of the total number of the blue cells stained by X-gal. A minimum of 300 cells was counted for each data point.
Measurement of CPP-32 Activity-Apoptosis was monitored with the ApoAlert caspase (CPP-32) assay kit using the (acetyl-L-aspartyl-Lglutamyl-L-valyl-L-aspartic acid ␣-(4-trifluoromethyl-coumacyl-7-amido)) substrate (CLONTECH, Palo Alto, CA). HEK-293 cells (3.0 ϫ 10 5 cells/60-mm dish) were transfected with 22 g of antisense or sense oligonucleotide for PPAR␦ using HVJ liposome (5), incubated for 48 h at 37°C, and cotransfected with 3 g of expression vector for PGISwt, PGISC441A, or mock vector in the presence of additional 3 g of antisense or sense oligonucleotide for PPAR␦. After 36 h, CPP-32 activity was determined according to the manufacturer's instructions
Immunoprecipitation of Cox-1-Monolayers of HEK-293 cells in a 225-cm 2 flask (3.0 ϫ 10 6 cells) were washed three times with PBS, pH 7.4, and suspended in 1 ml of PBS, pH 7.4, containing 10 mM EDTA, 0.1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 10 M leupeptin, 10 g/ml antipain, 10 M pepstatin (buffer A), and sonicated three times at 150 watts for 5 s on ice. The homogenate was centrifuged at 10,000 ϫ g for 10 min, and the supernatant was centrifuged at 100,000 ϫ g at 4°C for 1 h. Pellets were suspended in 0.5 ml of ice-cold buffer A containing 1% Tween 20, sonicated three times at 150 watts for 15 s on ice, and centrifuged at 100,000 ϫ g at 4°C for 1 h. The solubilized protein (800 g) was incubated with protein G-Sepharose (150 l) preincubated with control IgG for 2 h at 4°C as a preclearing step. After pelleting the protein G-Sepharose, COX-1 polyclonal IgG or control IgG coupled to protein G-Sepharose was added to a half of resulting supernatant and incubated for 3 h at 4°C. Protein G-Sepharose was then washed five times with 1 ml of the same buffer, mixed with 50 l of sample buffer under nonreducing condition, heated for 5 min at 100°C, subjected to 10% SDS-polyacrylamide gel electrophoresis, and transferred onto Immobilon-P as described above. Membrane was then subjected to immunoblotting analysis using COX-1 polyclonal antiserum.
Assay of 6-Keto-PGF 1␣ and cAMP-PGI 2 production was determined in HEK-293 cells (1.0 ϫ 10 6 /100-mm dish) cotransfected with expression vector for PGISwt, PGISC441A, or mock vector with or without COX-1 or COX-2 vector. After 24 h of transfection, medium was removed and serum-free medium containing 0 or 10 M arachidonic acid was added. After 48 h, incubation media were collected and stored at Ϫ20°C before assay. Amounts of 6-keto-PGF 1␣ were measured using an ELISA kit (Cayman Chemical Co.).
For cAMP assay, HEK-293 or BAEC (2.0 ϫ 10 5 cells/well in 6-well plates) were washed once in serum-free DMEM, followed by incubation with several concentrations of iloprost or cPGI for 24 h at 37°C. Reactions were terminated by aspiration of the medium and addition of 2 ml of 5% trichloroacetic acid. The cells were cooled to 4°C, cAMP was extracted with extraction buffer (65% ethanol containing 5 mM isobutylmethylxanthine, Sigma), and lysates were cleared by spinning at 10,000 ϫ g for 5 min and dried under vacuum. Samples were reconstituted in assay buffer, and cAMP was quantified using an ELISA kit (Amersham Pharmacia Biotech). 3 H]iloprost (0.05 Ci/ml) for 0 -180 min. Cells were washed with ice-cold PBS, harvested, and homogenized using a Dounce homogenizer in three volumes of homogenization buffer (10 mM Hepes, pH 7.5, 250 mM sucrose, 0.1 mM EDTA, 1.5 mM dithiothreitol, 10 g/ml trypsin inhibitor, 10 g/ml leupeptin, 2 g/ml aprotinin, and 1.0 mg/ml phenylmethylsulfonyl fluoride). Homogenates were centrifuged at 1450 ϫ g for 10 min. The supernatant was used as the cytoplasmcontaining fraction. Nuclei and plasma membranes were isolated from the resulting pellets. The pellet was resuspended in ice-cold homogenization buffer. The solution containing the resuspended pellet was adjusted to a final concentration of 1.6 M sucrose by addition of homogenization buffer with a high density sucrose solution. A two-layer step gradient was set up by layering 250 mM sucrose homogenization buffer over the 1.6 M sucrose suspension and centrifuged at 70,900 ϫ g for 60 min. The band at the gradient interface (250 mM and 1.6 M sucrose) was collected and used as the plasma membrane fraction. The pellet produced after the gradient centrifugation containing the nuclear fraction was collected and used for the nuclei fraction. The [ 3 H]iloprost-derived radioactivity of each fraction or whole cells was determined by liquid scintillation counting.
Oligonucleotides and Luciferase Assay-Oligonucleotides dS, 5Ј-AA-GAGGAGGAGAAAGAGGA-3Ј corresponding to the human PPAR␦ cDNA (32) sense sequence (nucleotide residues 38 -56); dAS, 5Ј-TC-CTCTTTCTCCTCCTCTT-3Ј, the antisense sequence; aS, 5Ј-CTCGGT-GACTTATCCTGTG-3Ј corresponding to the human PPAR␣ cDNA sense sequence (nucleotide residues 237-255); and the antisense sequence aAS, 5Ј-CACAGGATAAGTCACCGAG-3Ј, were synthesized. These oligonucleotides were transfected into cells using the HVJ liposome method (3). Each oligonucleotide (22 g) was mixed with a nuclear protein, high mobility group-1. HVJ liposomes were prepared by mixing dried lipids (phosphatidylserine/phosphatidylcholine/cholesterol, 1:4.8:2, w/w/w) with UV light-inactivated HVJ virus. After an incubation and sucrose gradient centrifugation, the top layer was collected and used for transfection. After 48 h of transfection the cells were used for apoptosis assay and PPAR-responsive element (PPRE) reporter assay. The PPREx3-luciferase reporter vector, which contains three copies of PPRE for hydroxymethylglutaryl-CoA reductase (33) for PPAR␦ or mutant PPAR␦ and PGISwt, PGISC441A, or mock vector using LipofectAMINE. The total amount of DNA was kept at 2 g by the addition of control DNA (pCMV-7). After another 24 h, the cells were harvested and the luciferase and ␤-galactosidase activities were quantified. The luciferase activity of the extract was normalized with ␤-galactosidase activity.
Construction of Expression Vectors for PPAR␦ and PPAR␦ L431A/ G434A-The cDNA for PPAR␦ was isolated by PCR amplification. The poly(A) ϩ RNA was extracted from 2.0 ϫ 10 6 cells of mouse vascular smooth muscle-derived SVS30 cells using a FastTrack 2.0 kit (Promega). The poly(A) ϩ RNA was reverse-transcribed by extension with Superscript reverse transcriptase (Life Technologies, Inc.) and a specific antisense primer complementary to the sequence located in the 3Ј-region of the cDNA for PPAR␦: 5Ј-TTAGTACATGTC-CTTGTAGATTTC-3Ј; the reverse-transcribed cDNA was used for the following PCR amplification. The PPAR␦ cDNA was amplified using the primers Pdw5 (5Ј-GAAAGCTTGTCGACCCACCATGGAA-CAGCCACAG-3Ј) and Pdw3 (5Ј-GTCTAGAGGATCCTTAGTACAT-GTCCTTGTAGAT-3Ј). Pdw5 or Pdw3 has HindIII or BamHI restriction site (underlined, respectively). PCR was performed for 35 cycles with a temperature profile of 10 s at 94°C, 30 s at 55°C, and 4 min at 72°C using KOD polymerase (Toyobo, Osaka, Japan). The amplification products were purified in 1% agarose gel using a Qiagen gel extraction kit. The isolated DNA was inserted into the HindIIIBamHI site of pBluescript II vector (Stratagene, La Jolla, CA) and sequenced using an Applied Biosystems model 310 genetic analyzer. For construction of an expression vector for PPAR␦, PCR-derived cDNA for PPAR␦ was excised from the pBluescript vector with HindIII and BamHI and religated into the pcDNAIII vector (Invitrogen, Groningen, The Netherlands). The PPAR␦L431A/G434A double mutant was generated by site-directed mutagenesis of wild-type receptor. The oligonucleotide used in mutagenesis was Pdm3 (5Ј-GTACATGTCCTTGTAGATCGCCTGGAGCGCGGGGTGCAGC-3Ј), and the construct was verified by sequencing. Pdm3 has two mutated sites (underlined). The products were purified, subcloned into the HindIII-BamHI site of pBluescript II, and inserted into the HindIIIBamHI site of pcDNAIII vector.
RESULTS AND DISCUSSION
An expression vector encoding human PGIS (29) or control vector was transfected into HEK-293 cells, and cell viability was determined. As shown in Fig. 1A , we observed a significant decrease in the viability of the cells transfected with the PGIS expression vector, whereas no change in viability was seen in the cells transfected with a mock vector. Moreover, transfection of the PGIS expression vector into HEK-293 cells resulted in significant morphological changes, including membrane blebbing and cell body shrinkage (Fig. 1B, left panel) , features typical of apoptosis (34) . When the histone-associated DNA fragments (mono-and oligonucleosomes) in cytosol fractions of the cells were measured by ELISA, the amounts of DNA fragments in the cells transfected with the PGIS expression vector increased gradually after 36 h of transfection (Fig. 1C) . However, cell morphology and contents of DNA fragments were not changed in cells transfected with the mock vector (Fig. 1, B and  C) . These data indicate that transfection with the PGIS expression vector causes a decline in cell viability and an increase in apoptotic cell death in HEK-293 cells. There is no detectable endogenous PGIS in HEK-293 cells (29) . A significant amount of endogenous COX-1, which synthesizes PGH 2 , a substrate for PGIS, was detected in the HEK-293 cells by immunoprecipitation (Fig. 1D) , although it has been reported that expression of both COX-1 and -2 in the cells is undetectable by immunoblotting (35) . As shown in Fig. 1E , overexpression of COX-1 or COX-2 alone in the HEK-293 cells did not produce apoptotic changes, suggesting that expression of PGIS is required for the apoptotic morphological changes in these cells. In contrast, overexpression of either COX-1 or COX-2 in bovine aortic endothelial cells (BAEC), which constitutively express PGIS at relatively high levels, increased apoptotic cell death significantly. It has been reported that overexpression of COX-2 in a gastrointestinal epithelial cell line, in which PGE 2 is the major metabolite of PGH 2 (36) , is associated with inhibition of apoptosis (37) . Overexpression of COX-2 in immortalized vascular endothelial cells, in which PGI 2 is a major metabolite of PGH 2 , slows growth and increases cell death (38) . COX-1 overexpression in the immortalized vascular endothelial cells inhibited the growth rate and enhanced apoptosis induced by TNF, which induces expression of COX-2 and PGIS (30, 37) . These lines of evidence all suggest that PGI 2 induces apoptotic cell death. The relationship between apoptosis and PGIS gene expression, however, has been unknown.
To examine the possibility that PGIS is involved in inducing apoptosis, the expression vector for wild-type human PGIS (PGISwt) or the catalytically inactive mutant PGISC441A (29) was transfected into HEK-293 cells under the same conditions. Immunofluorescence staining was performed using an anti-PGIS polyclonal antibody to confirm expression of these PGISs in the cells. At the same time, the condensation of chromatin, a typical morphological change associated with apoptosis, was measured using the fluorochrome bisbenzimide (Hoechst 33258) dye staining method (39) . As shown in Fig. 2, A and B , the cells expressing PGISwt were stained coincidentally and specifically by Hoechst 33258, and the genomic DNA extracted from these cells showed laddering (Fig. 2G) . Although the mutant PGISC441A protein was expressed at levels similar to those of the native enzyme, the PGIS-positive cells expressing PGISC441A protein were not stained by Hoechst 33258 (Fig. 2,  C and D) . The increase in the number of apoptotic Hoechst 33258-positive cells was time-dependent (Fig. 2H) . The number of Hoechst 33258-positive cells relative to the number of cells expressing native PGIS was decreased by 32% when the cells were treated with 100 M U46619, an inhibitor of PGIS (40) , or by 48% when cells were treated with 100 M aspirin, a COX inhibitor (Fig. 2H) . These partial inhibitions may reflect the apoptosis-inducible activities by U46619 and aspirin (41, 42) . Additionally, when the cells were transfected with increasing amounts of the PGISwt expression vector, both the amount of PGIS protein expressed in the cells and the numbers of apoptotic cells were increased concomitantly (Fig. 2I) ; in contrast, when the mutant PGISC441A expression vector was transfected into HEK-293 cells under the same conditions, the number of apoptotic cells did not increase, although the level of expression of PGISC441A protein was the same as that of PGISwt. Essentially identical results were obtained with CV-1 and Caco-2 cells (data not shown). These results establish that the increase of apoptosis of HEK-293 cells requires expression of catalytically active PGIS. PGI 2 production by the cells transfected with PGISwt expression vector was measured using an ELISA. The amount of 6-keto-PGF 1␣ , the stable hydrolysis product of PGI 2 , released into the culture medium was correlated with the frequency of apoptosis (Fig. 3, A and B) . Cotransfection of COX-1 plasmid with PGISwt into the cells and/or treatment of the cells with arachidonic acid resulted in increase of PGI 2 production and apoptosis. Furthermore, cotransfection of COX-2 into the cells with the PGISwt also increased PGI 2 production and apoptosis. Addition of arachidonic acid to the cells enhanced both PGI 2 production and apoptosis. When the PGISC441A expression vector was used in a parallel experiment, neither PGI 2 production nor apoptosis was increased in the cells.
Overexpression of COX-1 or COX-2 in BAEC, which express PGIS constitutively, increased apoptosis (Fig. 4) . There was essentially no difference in induction of apoptosis between coexpression with COX-1 or COX-2. These findings also indicate that PGI 2 produced by PGIS is involved in the process of apoptosis.
The next question we addressed is which signaling cascade contributes to apoptosis induced by PGI 2 . We examined the effect of PGI 2 on the cells using iloprost, a stable PGI 2 analog. When the cells were incubated with [ 3 H]iloprost, the radioactivity was recovered exclusively in the plasma membrane fractions (Fig. 5) . Treatment of the cells expressing PGISwt or PGISC441A with various concentrations of iloprost (0, 1, 10, 100 M) did not induce or enhance apoptosis (Fig. 6A ) but did cause increases in cAMP at higher concentrations (Fig. 6B) . Both extracellular iloprost and PGI 2 probably raise the intracellular concentrations of cAMP by activating the PGI 2 receptor IP and/or perhaps the prostaglandin E receptors EP2 (43) and EP4 (44) . Essentially no expression of IP mRNA was detected in HEK-293 cells by reverse transcriptase-PCR, however, it has been reported that EP receptors are expressed in HEK-293 cells and that PGE 1 raises the intracellular concentration of cAMP (45) . Thus, it is likely that high concentrations of iloprost can stimulate cAMP accumulation through EP2 and/or EP4 receptors in the cells. Nevertheless, the number of cells undergoing apoptosis did not increase in response to iloprost nor did treatment of the cells with dibutyryl cyclic AMP (dbcAMP) promote apoptosis (Fig. 6C) . In fact, both iloprost and dbcAMP inhibited apoptosis of these cells somewhat (Fig.  6, A and C) . Apoptosis is usually associated with activation of protein kinases (46) . To examine the correlation between protein kinase pathways and PGI 2 -mediated apoptosis, cells were treated with the protein kinase inhibitor H-7, which is an equipotent inhibitor of cAMP-dependent protein kinase, cGMPdependent protein kinase, and lipid-dependent protein kinase C (47) . H-7 did not block but actually enhanced somewhat PGI 2 -mediated apoptosis in HEK-293, CV-1, and Caco-2 cells (Fig. 6C) suggesting that all of these three types of protein kinases are involved in the induction of PGI 2 -induced apoptosis. Moreover, RpcAMP, an antagonist of cAMP, sig- nificantly enhanced PGI 2 -mediated apoptosis in these cells. Our data suggest that there is a novel PGI 2 signaling pathway that induces apoptosis independent of IP and EP receptor signaling.
PPARs are nuclear hormone receptors and, as such, are ligand-activated transcription factors (15) . Ligands for these receptors include hypolipidemic agents such as clofibrate, various fatty acids, and some arachidonic acid metabolites. PPARs activate their target genes upon binding to PPAR-response elements (PPREs) in promoters of target genes. PPAR␣ is highly expressed in hepatocytes, cardiomyocytes, enterocytes, and proximal tubule cells of the kidney (48) . PPAR␣ can inhibit apoptosis in hepatocytes (49) or can promote apoptosis in human macrophages activated with tumor necrosis factor-␣ (25). PPAR␦ is expressed ubiquitously and often at higher levels than either PPAR␣ or PPAR␥ (50) . Iloprost, carbaprostacyclin, and PGI 2 can activate recombinant PPAR␦ when it is overexpressed in CV-1 (51) or colorectal cancer-derived U2OS cells (28) . PPAR␦ plays a central role in fatty acid-controlled differentiation of preadipose cells (20) and in embryo implantation and decidualization (30) . Moreover PPAR␦, with its broad binding specificity, may have wide-ranging activities associated with the maintenance of molecular and cellular homeostasis such as body size, myelination of the corpus callosum, and epidermal cell proliferation (52) . It has also been reported that inhibition of PPAR␦ activity by nonsteroidal anti-inflammatory drugs suppressed tumorigenesis (22) . However, the relationship between apoptosis and PPAR␦ activated by endogenous PGI 2 has not been resolved.
To determine if PPARs are involved in apoptosis induced by intracellular PGI 2 , the effects of antisense oligonucleotides for PPAR␣ and PPAR␦ on PGI 2 signaling were examined. When a PPAR␣ antisense oligonucleotide was transfected into HEK-293 cells expressing PGISwt, expression of PPAR␣ was suppressed ( Fig. 7A) and apoptosis was not inhibited (Fig. 7B, left  panel) . The cells transfected with the PPAR␣ sense oligonucleotide also showed no marked changes in apoptosis. These results suggest that PPAR␣ may play an important role in maintaining the viability of HEK-293 cells, and that PGI 2 -mediated apoptosis is not promoted through PPAR␣. These findings suggested to us that endogenous PPAR␦ might be a second PGI 2 receptor that acts as the key signaling protein in PGI 2 -mediated apoptosis. To investigate this directly, we examined HEK-293 cells transfected with a PPAR␦ antisense oligonucleotide. After 48 h, suppression of the PPAR␦ protein expression was confirmed by immunoblotting (Fig. 7A) . The morphology of the cells treated with the PPAR␦ antisense oligonucleotide was normal, and the number of cells was in- creased. When PGISwt expression vector was cotransfected along with the antisense oligonucleotide for PPAR␦, PGI 2 -mediated apoptosis was reduced significantly (Fig. 7B, right panel) , as evidenced by a decrease in apoptotic cells bearing the antisense oligonucleotide. As shown in Fig. 7C , the luciferase activity of the PPRE-Luc reporter vector coexpressed with PGISwt in the HEK-293 cells, which were treated with the PPAR␦ antisense oligonucleotide, was decreased significantly. Moreover, the decrease in luciferase activity was correlated with the decrease in caspase activity (Fig. 7D) .
To test whether PPAR␦ activation by intracellular PGI 2 is necessary for PGI 2 -mediated apoptosis, a mutant PPAR␦ was generated by site-directed mutagenesis. The conserved hydrophobic and charged residues (Leu 431 and Glu 434 ) in the putative ligand-binding domain of PPARs (53) were both mutated to alanine (Fig. 8A) . It has been reported that a dominant-negative mutant of PPAR␥ was obtained by double mutation at positions Leu 468 and Glu 471 (53) , which correspond to Leu 431 and Glu 434 in PPAR␦. As shown in Fig. 8B , the mutant PPAR␦ exhibited markedly reduced transactivation, thus, this mutant functions as a dominant-negative inhibitor of wild-type receptor. As shown in Fig. 8, B and C, expression of PPAR␦L431A/ G434A with PGISwt antagonized the PGI 2 -mediated PPAR␦ activation and apoptosis was blocked completely. These results were consistent with the concept that PGI 2 -mediated apoptosis depends on activation of PPAR␦ by PGI 2 .
We have shown that activation of endogenous PPAR␦ by intracellular PGI 2 or a metabolite of PGI 2 results in activation of the apoptosis pathway. This, in turn, suggests that PGI 2 can interact with both a nuclear PPAR␦ and a cell surface IP (or EP) receptor coupled to increases in cAMP. These signaling pathways have opposing biological effects on cell apoptosis and/or viability, respectively. One question arises from our studies, Why don't endothelial cells and vascular smooth muscle cells expressing PGIS endogenously undergo apoptosis? One possibility is that the IP receptor/cAMP/protein kinase pathway serves to protect these cells from PGI 2 -mediated apoptosis primarily, because vascular endothelial cells and vascular smooth muscle cells express IP receptors, which can, in turn, lead to increases in cAMP levels at low concentrations of PGI 2 . In contrast, cells such as HEK-293 cells that lack the IP receptor easily undergo PGI 2 -mediated apoptosis. To verify this possibility, HEK-293 and BAEC were treated with a specific cAMP antagonist, RpcAMP. As shown in Fig. 9A , BAEC were highly sensitive to RpcAMP, and apoptosis was increased significantly in the cells treated with RpcAMP. However, HEK-293 cells did not show any in the degree of apoptosis when 4 cells/well in 12-well plates) were cultured in serum-free DMEM containing RpcAMP (0, 0.1, 1, 10, 100 M) for 24 h at 37°C, and the nucleosomes released during apoptosis of the cells were measured as described under "Experimental Procedures" (A). BAEC transfected with PPRE-luciferase reporter vector were cultured in serum-free DMEM containing cPGI (0, 1, 10, 100, 500 nM) or iloprost (0, 1, 10, 100, 500 nM) for 24 h at 37°C, and luciferase activity was measured (B, left panel). The intracellular cAMP accumulation in BAEC cultured in serum-free DMEM containing cPGI (0, 1, 10, 100, 500 nM) or iloprost (0, 1, 10, 100, 500 nM) for 24 h at 37°C was measured (B, right panel). BAEC were treated with cPGI (0, 1, 10, 100, 500 nM) or iloprost (0, 1, 10, 100, 500 nM) in the presence or absence of 100 nM RpcAMP, and apoptosis was measured (C). Results represent the mean Ϯ S.D. of three experiments.
exposed to the same conditions. As shown in Fig. 9B , a membrane-permeable PGI 2 analog, carbaprostacyclin (cPGI), activated PPRE-Luc activity (left panel) with a concomitant accumulation of intracellular cAMP (right panel) in BAEC. In contrast, iloprost did not increase luciferase activity, although the intracellular concentration of cAMP was increased. As shown in Fig. 9C , cPGI and iloprost did not induce apoptosis in BAEC, but cPGI strongly enhanced apoptosis in the presence of RpcAMP, which was not observed with membrane-impermeable iloprost. These data support the possibility that cAMP produced by the PGI 2 -IP-cAMP pathway serves to protect vascular endothelial cells from intracellular PGI 2 -PPAR␦-mediated apoptosis. In addition, there may be intricate mechanisms for controlling cell fate involving PGI 2 , PPAR␦, and the G protein-coupled PGI 2 receptors. Further characterization of the PGI 2 signaling cascade, including the PPAR␦ pathway, is underway in our laboratory.
